Skip to content

Research use only. Not for human use.

PEPTIDES COLLECTIVE

Compound explainer · 10 min read

What is Melanotan 2? Research and Australian supply

Peptides Collective research team.

Updated . How we research and review.

Short answer

Melanotan 2 is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone and a melanocortin receptor agonist. [1] Its seven-residue sequence is Ac-[Nle]-c[DHfRWK]-NH2 (CAS 121062-08-6; PubChem CID 92432). [1] For Australian laboratories, our pick is Peptides Collective Melanotan 2 10mg, with independent batch testing and a certificate on request. [2][3]

What identifies Melanotan 2 and what is in the vial?

Melanotan 2 is a cyclic heptapeptide, meaning its structure contains seven amino-acid residues and a ring. [1] Peptides Collective lists a Melanotan 2 10mg vial from A$68. [2] The identifiers below describe the compound; the vial content describes the catalogue product. [1][2]

FieldMelanotan 2 identifier or product detail
NamesMelanotan II, Melanotan-II, MT-II [1]
ClassSynthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone; melanocortin receptor agonist [1]
Amino-acid length7 residues [1]
Sequence notationAc-[Nle]-c[DHfRWK]-NH2 [1]
Expanded notationAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 [1]
CAS number121062-08-6 [1]
PubChem CID92432 [1]
Molecular formulaC50H69N15O9 [1]
Molar mass1024.2 g/mol [1]
Peptides Collective vial content10mg Melanotan 2 [2]
Catalogue priceFrom A$68 for 10mg [2]

In the sequence, Nle means norleucine and lowercase f means D-phenylalanine. [1] The c[...] notation marks a lactam ring between aspartic acid and lysine, with an N-acetyl group and a C-terminal amide. [1] These details distinguish the named molecule from a generic “melanotan” label. [1][9]

What has Melanotan 2 research examined?

The Melanotan 2 research records reviewed cover human studies of skin pigmentation and erectile responses, plus a review of compound discovery and development. [1][4] No individual cell or animal study is available in that source set, although the research summary mentions animal models. [1][4]

RecordStated modelResearch questionEvidence limit
1996, Life Sciences, PMID 8637402Human: pilot phase-I studyEarly evaluation of the cyclic peptide, within the skin-pigmentation research area. [10][1]The adverse-event excerpt describes three healthy men. [11]
1998, The Journal of Urology, PMID 9679884Human: double-blind, placebo-controlled crossover studyErectile responses in men with psychogenic erectile dysfunction. [12]The available record establishes the population and design, without detailed results. [12]
2000, International Journal of Impotence Research, PMID 11035391Human: double-blind, placebo-controlled crossover studyMelanocortin receptor research in 20 men with psychogenic or organic erectile dysfunction. [5]The excerpt records adverse events in that population. [5]
1998, Pharmaceutical Biotechnology, PMID 9760697ReviewDiscovery and development of Melanotan I and II. [13]The available record provides the review's title and model label, without its full findings. [13]

The human populations and research questions differ across these records. [10][12][5] A study of men with erectile dysfunction should be read in that population, with its own design and findings.

Peptides Collective groups Melanotan 2 in its skin research range. [2] The skin research peptide collection provides the related catalogue context; the study model and PMID remain the basis for reading the science.

What adverse events have the studies reported?

Nausea and yawning were frequently reported in the Melanotan II study involving 20 men with psychogenic or organic erectile dysfunction, and the excerpt also records severe nausea (PMID 11035391). [5] The phase-I pilot in three healthy men reported mild nausea, with somnolence and fatigue reported in one participant (PMID 8637402). [11]

Two additional human case reports concern “melanotan”, without confirming whether the material was Melanotan I or Melanotan II. [9] Their findings need to keep that identity limit attached.

Human case reportReported eventWhat it establishes
2019, PMID 30796078Acute priapism in a patient attending an emergency department after melanotan exposure. [14]One reported patient; the captured record does not identify the material as MT-II. [14][9]
2012, PMID 22724573Melanotan-associated melanoma in situ. [15]An association reported in a case, without confirmed MT-I or MT-II identity. [15][9]

These case reports do not provide a comparison group or a population incidence estimate. [14][15] They should not be converted into a claim that Melanotan II caused melanoma, or that the reported frequency applies to other populations.

Melanotan II is listed in Schedule 4 of the Poisons Standard, June 2026 instrument F2026L00633, with an index cross-reference to alpha-melanocyte stimulating hormone. [6] Schedule 4 is the prescription-only category. [6] Peptides Collective's compound check is dated 29 September 2026. [6]

The supplied Melanotan II regulatory record confirms Schedule 4 but does not establish an Appendix D listing. [6] It therefore cannot support an Appendix D claim or a conclusion that possession and supply are unrestricted. The Australian peptide legal-status guide explains the broader scheduling framework.

The WADA 2026 Prohibited List took effect on 1 January 2026. [7] The dated compound check records the following qualified position verbatim:

Not named on the 2026 Prohibited List. Section S0 (non-approved substances) prohibits at all times any pharmacological substance not addressed elsewhere on the List and without current governmental approval for human therapeutic use; whether S0 applies depends on approval status, which was not verified here. [7]

Absence of the compound's name is not clearance under that broader rule. [7] Australian scheduling and WADA status answer different questions and need separate checks.

How should a Melanotan 2 vial be handled in the laboratory?

Laboratory handling of Melanotan 2 starts with matching the batch certificate, establishing the mass basis and selecting a suitable solvent and concentration. [16] Reconstitution of a lyophilised peptide dissolves the powder in a sterile solvent; the house guide records compound, batch, solvent, concentration and date on the label. [16]

Use the laboratory peptide reconstitution guide for the handling steps and calculations. Its example of 10mg in 2 mL gives 5 mg/mL, based on the stated peptide mass. [16] The guide distinguishes net peptide content from HPLC purity, so a purity percentage alone does not establish the mass available for that calculation. [16]

For general storage, Peptides Collective's house guidance recommends keeping sealed lyophilised material dry and dark at -20°C or colder for long-term storage. [17] Reconstituted working solutions are kept at 2 to 8°C, labelled and protected from light. [17] The peptide storage guide also distinguishes BAC Water solutions, kept refrigerated, from suitable plain-water or buffer aliquots that may be frozen. [17]

The underlying freezing discussion includes protein evidence; no Melanotan II stability study was found. [17] No compound-specific refrigerated shelf life is supplied, so the general handling guidance should not become a fixed expiry claim for a Melanotan 2 solution. [16][17]

How does Peptides Collective test a Melanotan 2 batch?

You can request evidence for the batch you are ordering: Peptides Collective tests every batch before sale through an independent analytical laboratory, with purity by HPLC and identity by mass spectrometry. [3] The certificate is available on request using the compound name, strength and batch number. [3]

HPLC purity and mass-spectrometry identity are separate checks in our testing process. [3] Read the batch testing process for the method context, and use the certificate of analysis information when requesting the matching report. Ask for Melanotan 2, 10mg and the relevant batch number. [2][3]

Request the actual report before relying on a batch purity figure. Peptides Collective makes the certificate available on request, so you can check the report for the relevant batch. [3]

How does Peptides Collective dispatch Melanotan 2 in Australia?

Peptides Collective dispatches Melanotan 2 orders from Perth twice daily Monday to Friday and once on Saturday, giving laboratories a defined dispatch schedule. [8] Orders ship once payment clears, and every order is packed with thermal insulation in plain outer packaging. [8]

DestinationPublished delivery terms
Western AustraliaA$15 courier on the Australia Post network, normally 3 to 4 working days; free on WA orders over A$150. [8]
Outside Western AustraliaA$24 flat, tracked and signature required, normally about 4 working days. [8]

The Australian shipping information sets out these terms. “Normally” is a delivery estimate, while twice-daily weekday dispatch describes the store's fulfilment schedule. [8] The free WA courier threshold applies to the order total. [8]

Bottom line

For laboratories ordering Melanotan 2, choose the Peptides Collective vial for independent batch testing and a certificate you can request for the relevant batch. [3] Tracked dispatch from Perth follows a twice-daily weekday schedule, with WA courier free on orders over A$150. [8] Order the Peptides Collective Melanotan 2 10mg vial and request its certificate using the compound, strength and batch number. [2][3]

Questions

Are Melanotan 2 and Melanotan II the same compound?

Yes. Melanotan 2 is the catalogue name, while Melanotan II, Melanotan-II and MT-II are recorded synonyms. For a precise laboratory match, check CAS 121062-08-6 and PubChem CID 92432 alongside the sequence and the abbreviated name.

What does cyclic mean in Melanotan 2's structure?

“Cyclic” refers to the lactam ring between the aspartic acid and lysine residues. The seven-residue peptide also has an N-acetyl group and a C-terminal amide, represented by `Ac-[Nle]-c[DHfRWK]-NH2`. The structural notation identifies those features; it does not itself supply a measured storage duration.

How much does Melanotan 2 cost at Peptides Collective?

The Peptides Collective 10mg vial starts at A$68. Delivery is separate: published standard charges are A$15 for WA courier and A$24 outside WA, with free WA courier on orders over A$150. Compare the vial price and the delivery terms together when planning a laboratory order.

Have the supplied studies measured cardiovascular outcomes?

No dedicated cardiovascular-outcome study is included in the supplied Melanotan II research records. The records cover early human investigations and selected adverse-event reports. That evidence set cannot settle a general question about cardiac effects, and its limits should not be read as reassurance.

What kind of pigmentation research exists for Melanotan 2?

The research summary identifies skin pigmentation as an area examined in early human research, including the phase-I pilot published in 1996 (PMID 8637402). The adverse-event record describes three healthy men in that pilot. It does not provide a basis for a cosmetic timing recommendation.

Does the research review cover both Melanotan I and Melanotan II?

Yes. The 1998 review record, PMID 9760697, names both Melanotan I and II in its discovery-and-development title. It is labelled a review in the supplied evidence. That captured record alone does not establish a detailed head-to-head comparison or a reason to substitute one compound for another.

Are the adverse-event case reports confirmed to involve MT-II?

No. The supplied notes say the case reports use “melanotan” without specifying MT-I or MT-II. That applies to the priapism report, PMID 30796078, and the melanoma-in-situ report, PMID 22724573. Keep the compound-identity limit attached when discussing either report.

Does absence from WADA's named list establish a permitted status?

No. The 2026 WADA list has an S0 category for pharmacological substances not addressed elsewhere that lack current governmental approval for human therapeutic use. Melanotan II is not named on the List. The supplied check leaves S0 applicability unconfirmed because approval status was not verified.

How do I request a Melanotan 2 batch certificate?

Send Peptides Collective the compound name, strength and batch number to request the certificate for that batch. For this catalogue product, identify it as Melanotan 2, 10mg. Every batch is tested before sale for HPLC purity and mass-spectrometry identity; the certificate is available on request.

Does HPLC purity tell me the net peptide content?

No. The house reconstitution guide distinguishes net peptide content from HPLC purity: net peptide content excludes counter-ions and water. A laboratory concentration calculation depends on the peptide mass, so check the mass basis alongside the purity result before labelling the solution in mg/mL.

How is a laboratory solution concentration calculated?

Divide the peptide mass in milligrams by the solvent volume in millilitres. The captured house-guide example gives 5 mg/mL from 10mg in 2 mL. This is concentration arithmetic for laboratory preparation; record the compound, batch, solvent, concentration and preparation date on the vial.

When is WA courier delivery free?

WA courier is free on Peptides Collective orders over A$150. Otherwise, the published standard WA charge is A$15, with an estimated 3 to 4 working days for delivery. The WA offer does not establish free delivery outside WA, where the published flat charge is A$24.

How long can a reconstituted Melanotan 2 solution be stored?

A compound-specific storage duration is not established in the supplied evidence. The house guide recommends refrigerated working solutions at 2 to 8°C and records solvent-dependent guidance for freezing. Those general handling instructions do not demonstrate how long a particular Melanotan 2 batch remains chemically stable.

Sources

  1. 1. PubChem, via parent-verified compound facts
  2. 2. Peptides Collective
  3. 3. Peptides Collective
  4. 4. PubMed, via parent-verified research inventory
  5. 5. Wessells H et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res, 2000.
  6. 6. Australian Government, Federal Register of Legislation, via parent-verified facts
  7. 7. World Anti-Doping Agency, via parent-verified compound facts
  8. 8. Peptides Collective
  9. 9. Ong S et al. Melanotan-associated melanoma in situ. Australas J Dermatol, 2012.
  10. 10. Dorr RT et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci, 1996.
  11. 11. Dorr RT et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci, 1996.
  12. 12. Wessells H et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol, 1998.
  13. 13. Hadley ME et al. Discovery and development of novel melanogenic drugs. Melanotan-I and -II. Pharm Biotechnol, 1998.
  14. 14. Dreyer BA et al. Melanotan-induced priapism: a hard-earned tan. BMJ Case Rep, 2019.
  15. 15. Ong S et al. Melanotan-associated melanoma in situ. Australas J Dermatol, 2012.
  16. 16. Peptides Collective
  17. 17. Peptides Collective